Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions ...

U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...

(AP) — Nevro Corp. (NVRO) on Tuesday reported a loss ... The maker of an electrical implant that treats leg and back pain posted revenue of $105.5 million in the period, which also topped ...

March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company ... fusion potential compared to a posterolateral cylindrical-threaded single implant system.

U.S. permanent implant ... Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the ...